logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo merck_oncology

ESMO 2017: Combination immunotherapy with nivolumab or nivolumab plus ipilimumab in second- or third-line extends mesothelioma survival to 15 months

There is no approved second-line treatment for malignant pleural mesothelioma. MAPS2 study shows promising activity of checkpoint inhibitors.